An Qing Shi

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3, randomized, placebo-controlled study. This trial focuses on patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study aims to assess how AZD0780 compares to placebo in reducing the risk of major adverse cardiovascular events, also known as MACE-PLUS, over the course of the trial. Participants are randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study continues until a primary analysis censoring date, which may be up to approximately 54 months from randomization. After this, a study closure visit will be conducted as the final visit for each participant. During the study, participants will be regularly monitored for cardiovascular events including heart attacks, strokes, urgent coronary revascularizations, and other related outcomes. Researchers will track the time to first occurrence of these events as the primary outcome. Safety and other secondary outcomes like all-cause mortality will also be assessed. The total participation time can last up to about 54 months, with ongoing evaluations throughout this period.

Researchers are evaluating a new medicine called YL201 compared to the standard chemotherapy chosen by doctors in people with locally advanced or metastatic esophageal squamous cell carcinoma who have stopped responding to first-line treatment. The goal is to see if YL201 works better and is safer. The study is a large, randomized phase III trial involving multiple hospitals and also investigates how YL201 is processed in the body, immune reactions it might cause, and whether certain biological markers can predict its effects. Participants will be assigned to one of two groups one group receives YL201 alone, given as an intravenous infusion on the first day of each 3-week cycle. The other group receives a chemotherapy drug chosen by their doctor, which may be paclitaxel, docetaxel, or irinotecan, each given intravenously on specific schedules every 3 weeks. The study treatment continues as planned, with monitoring throughout the treatment period. During the study, participants will undergo regular evaluations including scans and laboratory tests to measure how well the treatments are working and to monitor side effects. The main outcome researchers will track is overall survival for up to about 36 months. They will also assess progression-free survival, response rates, duration of response, and adverse events during this time. The study will last until the end of 2028, with ongoing monitoring and data collection.

Researchers are conducting a large observational study called the China HeadAche Disorders Registry CHAIRS to better understand primary headaches and medication-overuse headaches MOH in patients aged 12 years and older. The study aims to collect detailed information including biomarkers, brain imaging, cognitive and genetic data, as well as social, demographic, medical, and treatment-related data. Long-term follow-up is planned to observe outcomes related to headache disorders over many years. Participants include those with various types of primary headaches such as migraine, tension-type headache, new daily persistent headache, and MOH. The study includes behavioral follow-up visits at multiple time points monthly for the first 18 months, then at 24 months, and annually thereafter. Some participants are observed during routine clinical use of treatments like Yangxue Qingnao Granules, Erenumab, and Eptinezumab, with treatment decisions made by their physicians and outcomes tracked over 12 weeks or longer. Throughout the study, participants undergo periodic assessments including MRI scans, cognitive tests like the Montreal Cognitive Assessment MoCA and Mini-Mental State Exam MMSE, and questionnaires evaluating headache impact, anxiety, depression, quality of life, sleep quality, and fatigue. Data on headache frequency, severity, medication use, and biological samples are collected. Follow-up can extend up to 10 years, allowing researchers to monitor long-term changes and outcomes related to headache disorders and treatments.

Researchers are establishing a standardized clinical database for patients with liver cancer, including hepatocellular carcinoma and related types, to support high-quality real-world clinical studies. This observational study is led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China USTC in collaboration with multiple centers nationwide. The purpose is to collect detailed clinical information to better understand liver cancer outcomes over time. Participants will receive routine clinical treatments for liver cancer, such as surgical resection, ablation, transarterial chemoembolization TACE, hepatic arterial infusion chemotherapy HAIC, and various anti-tumor drugs including immunologic, targeted, and chemotherapy agents. The study observes and records these standard treatments without assigning interventions. The research will track these patients in a cohort database to monitor their treatment and progression. During the study, participants will be followed for up to 10 years to assess overall survival, recurrence-free survival, and survival time after cancer recurrence. Researchers will collect blood and surgical tissue samples and perform regular follow-up visits to gather clinical data and pathology results. This long-term monitoring aims to provide comprehensive insights into liver cancer progression and treatment outcomes.

Researchers are evaluating the pain relief effects and safety of three drugsoliceridine, morphine, and sufentanilin patients undergoing elective lumbar spine surgery. This randomized controlled trial aims to compare these medications when used for postoperative pain control, focusing on how well they reduce pain during movement six hours after surgery. The study also examines side effects such as nausea, vomiting, sleepiness, breathing problems, and itching within the first 48 hours after surgery. Participants are randomly assigned to one of three groups to receive intravenous patient-controlled analgesia after their surgery. The oliceridine group receives a 1.5 mg loading dose followed by a continuous infusion of 0.01 mg per kilogram per hour. The morphine group receives a 4 mg loading dose followed by an infusion of 0.03 mg per kilogram per hour. The sufentanil group receives a 4 microgram loading dose followed by an infusion of 0.03 micrograms per kilogram per hour. Each infusion is diluted in 100 ml of saline and delivered at a rate of 2 ml per hour. During the study, participants pain levels are assessed using a Visual Analogue Scale both at rest and during movement at multiple time points up to 48 hours after surgery. Researchers also monitor sedation levels, the number of times patients use the pain control button, the need for extra pain medication, and vital signs shortly after the initial dose. The study lasts through the first 48 hours after surgery, focusing on both pain relief and safety outcomes to better understand how these medications compare.

This research aims to compare whether using different sizes of tracheal catheters causes less sore throat in women after thyroid surgery. It involves female patients aged 18 to 65 years with physical health status ranging from ASA I to III, all scheduled for thyroid surgery under general anesthesia. The study focuses on evaluating sore throat incidence and severity following the procedure. Participants are randomly assigned to one of three groups, each receiving a tracheal catheter with a different inner diameter 6.0 mm, 6.5 mm, or the traditional 7.0 mm size. The study monitors how each catheter size affects postoperative sore throat at multiple time points after surgery, specifically at 1 hour, 6 hours, 24 hours, and 48 hours. During the study, researchers record the presence and severity of sore throat at these times to assess differences among the groups. The trial includes women undergoing elective thyroid surgery under general anesthesia who meet the eligibility criteria. The study is expected to run until October 2026, with participant involvement mainly around the surgery and follow-up sore throat assessments.

Researchers are investigating whether vitamin D3 supplementation can improve cardiovascular metabolic health in Chinese adolescents who are overweight or obese and have vitamin D deficiency. This randomized controlled trial aims to compare changes in cardiometabolic risk between those receiving vitamin D3 and those receiving a placebo over a 12-week period. Participants will be randomly assigned to receive either vitamin D3 supplements or a placebo. The vitamin D3 group will take 2000 IU daily for the first 6 weeks, followed by 800 IU daily for the next 6 weeks. The placebo group will receive matching placebo capsules on the same schedule. For the first 6 weeks, doses are given every two weeks, then every three weeks for the following 6 weeks. During the study, researchers will monitor changes in cardiometabolic risk scores from the start to the end of the 12-week intervention. Additional measurements include body mass index, waist circumference, skinfold thickness, blood pressure, blood glucose, blood lipids, and the TyG index. Participants health and vitamin D levels will be assessed throughout to evaluate the effects of supplementation.

Researchers are evaluating the safety and effectiveness of two different durations of S-1 chemotherapy as additional treatment after surgery in patients with stage II gastric cancer. This study compares taking S-1 for 9 months versus taking it for 1 year following D2 lymph node dissection surgery. The goal is to see if 9 months of treatment is not worse than 1 year in terms of disease-free survival, overall survival, and safety. Participants will be randomly assigned to receive S-1 chemotherapy either for 9 months or for 1 year. Both groups will follow a treatment cycle of taking S-1 daily for 14 days, followed by a 7-day rest, repeating every 3 weeks. The dose of S-1 ranges from 80 to 120 mg per day. The study includes planned interim analyses to monitor safety and progress, with a final assessment after five years from the last patients enrollment. During the study, participants will have regular monitoring to assess disease-free survival at 3 years and overall survival at 5 years, as well as safety evaluations. Organ function and blood tests will be checked to ensure participants tolerate the treatment. The study aims to provide new guidance on the optimal duration of S-1 chemotherapy after surgery for gastric cancer, with involvement lasting several years including follow-up.

Researchers are evaluating the safety and effectiveness of atorvastatin in adults aged 18 to 80 years who have experienced spontaneous intracerebral hemorrhage ICH within 3 to 24 hours of symptom onset. This multicenter, prospective, randomized, open-label, blinded end-point PROBE study aims to determine if atorvastatin improves clinical outcomes compared to best medical treatment alone. The study focuses on patients with hematomas located in the supratentorial region and uses the modified Rankin Scale mRS to measure functional outcomes at 90 days. Participants will be randomly assigned to one of two groups one group will receive atorvastatin 20 mg once daily for 21 days along with best medical treatment BMT following current guidelines for ICH, while the other group will receive only BMT. The treatment period lasts for 21 days starting within 48 hours of symptom onset or last known well time. The study will monitor changes in hematoma and perihematomal edema volumes at specific time points during the first week after hemorrhage. During the trial, participants will undergo assessments including computed tomography CT scans to confirm ICH diagnosis and measure hematoma size, as well as evaluations using the Glasgow Coma Scale and mRS. Researchers will track functional independence and neurological outcomes at 90 7 days. Safety and adverse events will be monitored throughout the study. The total follow-up includes primary and secondary outcome measurements up to three months after treatment to evaluate the impact of atorvastatin on recovery.

Researchers are studying cardiovascular diseases CVD including coronary heart disease, atrial fibrillation, and chronic heart failure in participants aged 40 years or older. The study aims to describe how common chronic obstructive pulmonary disease COPD is among these participants and to observe how combined heart and lung care affects their short-term health outcomes. Approximately 3,000 participants will be enrolled, with about 1,000 in each disease group. The study uses a behavioral intervention that includes guideline education and implementation at both the investigator and patient levels. Investigators receive disease education before enrollment, and cardiologists and pulmonologists provide ongoing disease education and coordinated treatment every four weeks. Participants will be followed up every four weeks to manage their care and monitor progress. Participants will undergo spirometry testing and complete questionnaires to assess their lung and heart health. Researchers will measure COPD prevalence, hospitalization rates, symptom scores, lung function, and other heart and lung-related biomarkers over 12 weeks. The study includes assessments of treatment adherence and changes in health status through repeated evaluations at baseline and weeks 4, 8, and 12. Safety and outcomes will be closely monitored throughout the study period.